Fabiana Rollini, M.B.Ch.B. (M.D.)

Fabiana Rollini M.B.Ch.B. (M.D.)

Associate Professor & Medical Director, Cardiovascular Center Inpatient Services (CCU)

Department: Department of Medicine
Business Phone: (904) 244-2060
Business Email: Fabiana.rollini@jax.ufl.edu
Appointments and Locations

Clinical Profile

Specialties
  • Cardiovascular Disease
Languages
  • Speaks English, French and Italian

Publications

2025
Cangrelor in Patients With Cardiogenic Shock or Cardiac Arrest.
JACC. Cardiovascular interventions.18(7):863-865[DOI] 10.1016/j.jcin.2025.03.001.[PMID] 40240084.
PubMed·Publisher's Site
2025
Switching from cangrelor to oral P2Y12 inhibitors: a focused review on drug-drug interactions.
Expert opinion on drug metabolism & toxicology.21(1):29-40[DOI] 10.1080/17425255.2024.2418033.[PMID] 39407420.
2 citations·PubMed·Publisher's Site
2024
Clopidogrel-Mediated P2Y12 Inhibition According to Renal Function in Patients With Diabetes Mellitus and CAD.
JACC. Basic to translational science.9(7):865-876[DOI] 10.1016/j.jacbts.2024.03.003.[PMID] 39170956.
1 citations·PubMed·Publisher's Site
2024
Effect of lipid-lowering therapy on platelet reactivity in patients treated with and without antiplatelet therapy.
Minerva cardiology and angiology.72(5):489-505[DOI] 10.23736/S2724-5683.23.06411-6.[PMID] 37870424.
5 citations·PubMed·Publisher's Site
2024
International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention: 2024 Update.
JACC. Cardiovascular interventions.17(22):2639-2663[DOI] 10.1016/j.jcin.2024.08.027.[PMID] 39603778.
17 citations·PubMed·Publisher's Site
2024
P2Y12 Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention: The SWAP-AC-2 Study.
JACC. Cardiovascular interventions.17(11):1356-1370[DOI] 10.1016/j.jcin.2024.03.027.[PMID] 38597172.
6 citations·PubMed·Publisher's Site
2024
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study.
Thrombosis and haemostasis.124(3):263-273[DOI] 10.1055/a-2098-6639.[PMID] 37224883.
6 citations·PubMed·Publisher's Site
2024
Switching Platelet P2Y12 Receptor Inhibiting Therapies.
Interventional cardiology clinics.13(4S):e1-e30[DOI] 10.1016/j.iccl.2024.11.001.[PMID] 39674676.
PubMed·Publisher's Site
2024
Therapeutic Potential of FXI Inhibitors: Hype or Hope?
Drugs.84(9):1055-1070[DOI] 10.1007/s40265-024-02049-w.[PMID] 39073551.
8 citations·PubMed·Publisher's Site
2023
Acute myocardial infarction following 5-fluorouracil treatment.
Journal of geriatric cardiology : JGC.20(7):551-554[DOI] 10.26599/1671-5411.2023.07.008.[PMID] 37576478.
1 citations·PubMed·Publisher's Site
2023
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study.
JACC. Cardiovascular interventions.16(1):36-46[DOI] 10.1016/j.jcin.2022.10.034.[PMID] 36317958.
18 citations·PubMed·Publisher's Site
2023
Clinical and Pre-Clinical Pharmacokinetics and Pharmacodynamics of Bentracimab.
Clinical pharmacokinetics.62(5):673-692[DOI] 10.1007/s40262-023-01245-3.[PMID] 37118383.
2 citations·PubMed·Publisher's Site
2023
Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium.
Circulation.147(25):1933-1944[DOI] 10.1161/CIRCULATIONAHA.123.064473.[PMID] 37335828.
85 citations·PubMed·Publisher's Site
2023
Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications.
Expert review of clinical pharmacology.16(1):27-38[DOI] 10.1080/17512433.2023.2154651.[PMID] 36455906.
14 citations·PubMed·Publisher's Site
2023
Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis.
Thrombosis and haemostasis.123(6):576-584[DOI] 10.1055/a-2043-0346.[PMID] 36841245.
38 citations·PubMed·Publisher's Site
2023
First case of Arcobacter species isolated in pericardial fluid in an HIV and COVID-19 patient with worsening cardiac tamponade.
IDCases.32():e01771-[DOI] 10.1016/j.idcr.2023.e01771.[PMID] 37151209.
7 citations·PubMed·Publisher's Site
2023
Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.18(15):1254-1265[DOI] 10.4244/EIJ-D-22-00719.[PMID] 36602868.
12 citations·PubMed·Publisher's Site
2023
Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes.
Vascular pharmacology.149():107145-[DOI] 10.1016/j.vph.2023.107145.[PMID] 36720377.
3 citations·PubMed·Publisher's Site
2023
Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention.
Trends in cardiovascular medicine.33(3):133-138[DOI] 10.1016/j.tcm.2021.12.007.[PMID] 34936903.
30 citations·PubMed·Publisher's Site
2023
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) Study.
JACC. Cardiovascular interventions.16(20):2528-2539[DOI] 10.1016/j.jcin.2023.08.009.[PMID] 37609698.
9 citations·PubMed·Publisher's Site
2022
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
European heart journal.43(10):959-967[DOI] 10.1093/eurheartj/ehab836.[PMID] 34918066.
115 citations·PubMed·Publisher's Site
2022
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.
European heart journal. Cardiovascular pharmacotherapy.8(5):452-461[DOI] 10.1093/ehjcvp/pvab042.[PMID] 34114623.
2 citations·PubMed·Publisher's Site
2022
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
Journal of thrombosis and thrombolysis.54(3):461-469[DOI] 10.1007/s11239-022-02696-4.[PMID] 36048358.
5 citations·PubMed·Publisher's Site
2022
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention.
Nature reviews. Cardiology.19(12):829-844[DOI] 10.1038/s41569-022-00725-6.[PMID] 35697777.
57 citations·PubMed·Publisher's Site
2022
Patterns and Outcomes of Dual Antiplatelet Therapy Discontinuation After Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions.15(8):807-809[DOI] 10.1016/j.jcin.2022.02.048.[PMID] 35450680.
3 citations·PubMed·Publisher's Site
2022
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease.
Thrombosis and haemostasis.122(8):1341-1351[DOI] 10.1055/a-1730-8725.[PMID] 34983074.
18 citations·PubMed·Publisher's Site
2022
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study.
Journal of thrombosis and thrombolysis.54(3):373-381[DOI] 10.1007/s11239-022-02687-5.[PMID] 36036856.
9 citations·PubMed·Publisher's Site
2022
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.
European heart journal. Cardiovascular pharmacotherapy.8(7):728-737[DOI] 10.1093/ehjcvp/pvac022.[PMID] 35353154.
18 citations·PubMed·Publisher's Site
2022
Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention.
Pharmacogenomics.23(13):723-737[DOI] 10.2217/pgs-2022-0057.[PMID] 35938534.
33 citations·PubMed·Publisher's Site
2022
Reply: The Effects of Cangrelor on Platelet Aggregation in STEMI Patients: Methodological or Pharmacological Issues?
JACC. Cardiovascular interventions.15(2):230-231[DOI] 10.1016/j.jcin.2021.12.002.[PMID] 35057998.
1 citations·PubMed·Publisher's Site
2022
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.
European heart journal. Cardiovascular pharmacotherapy.8(7):677-686[DOI] 10.1093/ehjcvp/pvab070.[PMID] 34519777.
60 citations·PubMed·Publisher's Site
2021
Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study.
BMJ open diabetes research & care.9(1):-[DOI] 10.1136/bmjdrc-2020-001939.[PMID] 33637605.
29 citations·PubMed·Publisher's Site
2021
Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations.
Expert review of clinical pharmacology.14(8):963-978[DOI] 10.1080/17512433.2021.1927709.[PMID] 33993817.
35 citations·PubMed·Publisher's Site
2021
Genotype-Guided Antiplatelet Therapy in Patients With Coronary Artery Disease.
JACC. Cardiovascular interventions.14(7):751-753[DOI] 10.1016/j.jcin.2021.02.005.[PMID] 33744206.
2 citations·PubMed·Publisher's Site
2021
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Lancet (London, England).397(10283):1470-1483[DOI] 10.1016/S0140-6736(21)00533-X.[PMID] 33865495.
166 citations·PubMed·Publisher's Site
2021
Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor.
JACC. Cardiovascular interventions.14(21):2410-2412[DOI] 10.1016/j.jcin.2021.07.051.[PMID] 34736741.
4 citations·PubMed·Publisher's Site
2021
Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor.
Journal of thrombosis and thrombolysis.51(3):741-747[DOI] 10.1007/s11239-021-02386-7.[PMID] 33582955.
12 citations·PubMed·Publisher's Site
2020
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.
Thrombosis and haemostasis.120(1):83-93[DOI] 10.1055/s-0039-1695772.[PMID] 31470444.
18 citations·PubMed·Publisher's Site
2020
Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS-6 Study.
Circulation.142(15):1500-1502[DOI] 10.1161/CIRCULATIONAHA.120.048770.[PMID] 33044856.
10 citations·PubMed·Publisher's Site
2020
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study.
Journal of the American Heart Association.9(8):e015865-[DOI] 10.1161/JAHA.120.015865.[PMID] 32306797.
18 citations·PubMed·Publisher's Site
2020
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing.
JACC. Basic to translational science.5(5):419-428[DOI] 10.1016/j.jacbts.2020.02.009.[PMID] 32478205.
27 citations·PubMed·Publisher's Site
2019
Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine.
JACC. Cardiovascular interventions.12(16):1538-1549[DOI] 10.1016/j.jcin.2019.05.028.[PMID] 31377269.
29 citations·PubMed·Publisher's Site
2019
Endocarditis caused by Stenotrophomonas maltophilia-A rare presentation of an emerging opportunistic pathogen.
IDCases.17():e00556-[DOI] 10.1016/j.idcr.2019.e00556.[PMID] 31193238.
3 citations·PubMed·Publisher's Site
2019
Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.
JACC. Basic to translational science.4(7):763-775[DOI] 10.1016/j.jacbts.2019.07.011.[PMID] 31998847.
15 citations·PubMed·Publisher's Site
2019
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Circulation.139(14):1661-1670[DOI] 10.1161/CIRCULATIONAHA.118.038317.[PMID] 30630341.
118 citations·PubMed·Publisher's Site
2019
Switching Oral Anticoagulant Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions.12(23):2342-2345[DOI] 10.1016/j.jcin.2019.10.017.[PMID] 31806215.
1 citations·PubMed·Publisher's Site
2018
"Malignant" right coronary artery presenting as an ST-segment elevation myocardial infarction-a case report.
Journal of geriatric cardiology : JGC.15(6):467-468[DOI] 10.11909/j.issn.1671-5411.2018.07.001.[PMID] 30108621.
5 citations·PubMed·Publisher's Site
2018
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention.
Nature reviews. Cardiology.15(8):480-496[DOI] 10.1038/s41569-018-0049-1.[PMID] 29973709.
170 citations·PubMed·Publisher's Site
2018
Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
Journal of translational medicine.16(1):92-[DOI] 10.1186/s12967-018-1469-8.[PMID] 29642909.
47 citations·PubMed·Publisher's Site
2018
Diabetes and antiplatelet therapy: from bench to bedside.
Cardiovascular diagnosis and therapy.8(5):594-609[DOI] 10.21037/cdt.2018.05.09.[PMID] 30498684.
41 citations·PubMed·Publisher's Site
2018
Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy.
Progress in cardiovascular diseases.60(4-5):478-490[DOI] 10.1016/j.pcad.2017.12.004.[PMID] 29291426.
55 citations·PubMed·Publisher's Site
2018
Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.
Clinical pharmacology and therapeutics.104(4):664-674[DOI] 10.1002/cpt.1006.[PMID] 29280137.
93 citations·PubMed·Publisher's Site
2018
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.
Circulation.137(23):2450-2462[DOI] 10.1161/CIRCULATIONAHA.118.033983.[PMID] 29526833.
46 citations·PubMed·Publisher's Site
2018
Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.
Journal of cardiovascular pharmacology and therapeutics.23(1):23-37[DOI] 10.1177/1074248417708617.[PMID] 28565918.
17 citations·PubMed·Publisher's Site
2018
Role of genetic testing in patients undergoing percutaneous coronary intervention.
Expert review of clinical pharmacology.11(2):151-164[DOI] 10.1080/17512433.2017.1353909.[PMID] 28689434.
52 citations·PubMed·Publisher's Site
2018
Standard- and Low-Dose Ticagrelor After Percutaneous Coronary Intervention: Finding the Balance for Patients With Stable Coronary Artery Disease.
Circulation.138(13):1301-1303[DOI] 10.1161/CIRCULATIONAHA.118.036240.[PMID] 30354428.
2 citations·PubMed·Publisher's Site
2018
Syncope in a middle-aged man.
Emergency medicine journal : EMJ.35(6):395-401[DOI] 10.1136/emermed-2017-207381.[PMID] 29784832.
PubMed·Publisher's Site
2018
The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts.
Expert review of hematology.11(1):5-12[DOI] 10.1080/17474086.2018.1400378.[PMID] 29091481.
17 citations·PubMed·Publisher's Site
2018
The Quest for the Optimal Periprocedural Antithrombotic Treatment Strategy in ACS Patients Undergoing PCI.
Journal of the American College of Cardiology.71(11):1243-1245[DOI] 10.1016/j.jacc.2018.01.040.[PMID] 29544608.
6 citations·PubMed·Publisher's Site
2017
Antithrombotic therapy for patients with STEMI undergoing primary PCI.
Nature reviews. Cardiology.14(6):361-379[DOI] 10.1038/nrcardio.2017.18.[PMID] 28230176.
84 citations·PubMed·Publisher's Site
2017
Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status.
Thrombosis and haemostasis.117(5):940-947[DOI] 10.1160/TH16-09-0703.[PMID] 28300867.
20 citations·PubMed·Publisher's Site
2017
Crushed ticagrelor in comatose patients treated with primary percutaneous coronary intervention.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.12(14):1681-1683[DOI] 10.4244/EIJV12I14A276.[PMID] 28216470.
3 citations·PubMed·Publisher's Site
2017
De-Escalation of Platelet P2Y12 Receptor Inhibiting Therapy After Percutaneous Coronary Intervention: Does One Size Fit All?
JACC. Cardiovascular interventions.10(24):2571-2573[DOI] 10.1016/j.jcin.2017.10.007.[PMID] 29268887.
5 citations·PubMed·Publisher's Site
2017
Drug-Drug Interactions When Switching Between Intravenous and Oral P2Y12 Receptor Inhibitors: How Real Is It?
JACC. Cardiovascular interventions.10(2):130-132[DOI] 10.1016/j.jcin.2016.11.021.[PMID] 28104205.
8 citations·PubMed·Publisher's Site
2017
Impact of chronic kidney disease on platelet P2Y12 receptor signalling in patients with type 2 diabetes mellitus.
Thrombosis and haemostasis.117(1):201-203[DOI] 10.1160/TH16-08-0594.[PMID] 27786340.
6 citations·PubMed·Publisher's Site
2017
Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
Journal of the American Heart Association.6(4):-[DOI] 10.1161/JAHA.117.005650.[PMID] 28356282.
34 citations·PubMed·Publisher's Site
2017
Institutional profile: University of Florida Health Personalized Medicine Program.
Pharmacogenomics.18(5):421-426[DOI] 10.2217/pgs-2017-0028.[PMID] 28346068.
55 citations·PubMed·Publisher's Site
2017
International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies.
Circulation.136(20):1955-1975[DOI] 10.1161/CIRCULATIONAHA.117.031164.[PMID] 29084738.
275 citations·PubMed·Publisher's Site
2017
In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor-Mediated Signaling in Ticagrelor-Treated Patients.
JACC. Cardiovascular interventions.10(13):1374-1375[DOI] 10.1016/j.jcin.2017.04.027.[PMID] 28683943.
9 citations·PubMed·Publisher's Site
2017
Oral trans-mucosal administration of ticagrelor: is this really the future?
Thrombosis and haemostasis.117(5):826-828[DOI] 10.1160/TH17-03-0177.[PMID] 28331923.
1 citations·PubMed·Publisher's Site
2017
Percutaneous Interventional Repair of an Intraoperative Right Coronary Artery Tear.
JACC. Cardiovascular interventions.10(23):2464-2465[DOI] 10.1016/j.jcin.2017.07.039.[PMID] 29153495.
PubMed·Publisher's Site
2017
Reply: Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.
Journal of the American College of Cardiology.69(2):250-251[DOI] 10.1016/j.jacc.2016.09.982.[PMID] 28081837.
PubMed·Publisher's Site
2017
Switching from ticagrelor to clopidogrel: New answers and further questions.
Thrombosis and haemostasis.117(2):207-208[DOI] 10.1160/TH16-12-0909.[PMID] 28004060.
3 citations·PubMed·Publisher's Site
2017
Switching P2Y12 Receptor Inhibiting Therapies.
Interventional cardiology clinics.6(1):67-89[DOI] 10.1016/j.iccl.2016.08.006.[PMID] 27886824.
8 citations·PubMed·Publisher's Site
2017
The role of oral anticoagulant therapy in patients with acute coronary syndrome.
Therapeutic advances in hematology.8(12):353-366[DOI] 10.1177/2040620717733691.[PMID] 29204262.
17 citations·PubMed·Publisher's Site
2016
A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.
European heart journal.37(35):2722-30[DOI] 10.1093/eurheartj/ehv744.[PMID] 26848148.
51 citations·PubMed·Publisher's Site
2016
A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
Expert opinion on drug safety.15(2):275-85[DOI] 10.1517/14740338.2016.1133585.[PMID] 26680584.
14 citations·PubMed·Publisher's Site
2016
Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease.
Circulation journal : official journal of the Japanese Circulation Society.80(4):791-801[DOI] 10.1253/circj.CJ-16-0208.[PMID] 26984587.
17 citations·PubMed·Publisher's Site
2016
Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.
Journal of the American College of Cardiology.67(17):1994-2004[DOI] 10.1016/j.jacc.2016.02.045.[PMID] 27012781.
107 citations·PubMed·Publisher's Site
2016
Dual antiplatelet therapy after coronary stenting.
Expert opinion on pharmacotherapy.17(13):1775-87[DOI] 10.1080/14656566.2016.1202924.[PMID] 27309035.
11 citations·PubMed·Publisher's Site
2016
Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.
Thrombosis and haemostasis.115(3):622-31[DOI] 10.1160/TH15-06-0467.[PMID] 26633836.
19 citations·PubMed·Publisher's Site
2016
Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors.
Thrombosis and haemostasis.116(6):1060-1069[DOI] .[PMID] 27488362.
7 citations·PubMed·Publisher's Site
2016
New oral anticoagulants and dual antiplatelet therapy: Focus on apixaban.
International journal of cardiology.225():154-158[DOI] 10.1016/j.ijcard.2016.09.125.[PMID] 27723533.
PubMed·Publisher's Site
2016
Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
Circulation.134(11):780-92[DOI] 10.1161/CIRCULATIONAHA.116.023402.[PMID] 27559041.
77 citations·PubMed·Publisher's Site
2016
Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
JACC. Cardiovascular interventions.9(11):1089-98[DOI] 10.1016/j.jcin.2016.02.039.[PMID] 27013060.
34 citations·PubMed·Publisher's Site
2016
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.
Journal of the American College of Cardiology.67(10):1145-1154[DOI] 10.1016/j.jacc.2015.12.062.[PMID] 26965534.
102 citations·PubMed·Publisher's Site
2016
Switching P2Y12-receptor inhibitors in patients with coronary artery disease.
Nature reviews. Cardiology.13(1):11-27[DOI] 10.1038/nrcardio.2015.113.[PMID] 26283269.
138 citations·PubMed·Publisher's Site
2016
The Conundrum of Platelet P2Y12 Inhibition in ST-Segment Elevation Myocardial Infarction.
Circulation journal : official journal of the Japanese Circulation Society.80(12):2429-2431[DOI] .[PMID] 27795489.
3 citations·PubMed·Publisher's Site
2016
The Paradox of Smoking and Clopidogrel Effect　- Dr Jekyll or Mr Hyde?
Circulation journal : official journal of the Japanese Circulation Society.80(7):1529-31[DOI] 10.1253/circj.CJ-16-0508.[PMID] 27302849.
2 citations·PubMed·Publisher's Site
2016
Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction.
Trends in cardiovascular medicine.26(4):321-34[DOI] 10.1016/j.tcm.2015.08.002.[PMID] 26391344.
3 citations·PubMed·Publisher's Site
2015
[Non-cardiac surgery in patients with previous percutaneous coronary intervention according to the 2014 European guidelines].
Giornale italiano di cardiologia (2006).16(5):277-80[DOI] 10.1714/1870.20424.[PMID] 25994462.
PubMed·Publisher's Site
2015
Acute coronary syndromes: applying practice guidelines and defining the unmet need in clinical practice.
The American journal of cardiology.115(5 Suppl):1A-2A[DOI] 10.1016/j.amjcard.2015.01.001.[PMID] 25728970.
PubMed·Publisher's Site
2015
Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable patients with CAD treated with dual ANtiplatelet therapy) study.
Journal of thrombosis and thrombolysis.40(3):331-9[DOI] 10.1007/s11239-015-1203-9.[PMID] 25761430.
1 citations·PubMed·Publisher's Site
2015
Defining the link between chronic kidney disease, high platelet reactivity, and clinical outcomes in clopidogrel-treated patients undergoing percutaneous coronary intervention.
Circulation. Cardiovascular interventions.8(6):e002760-[DOI] 10.1161/CIRCINTERVENTIONS.115.002760.[PMID] 26056251.
13 citations·PubMed·Publisher's Site
2015
Drug-drug interactions between clopidogrel and novel cardiovascular drugs.
European journal of pharmacology.765():332-6[DOI] 10.1016/j.ejphar.2015.08.059.[PMID] 26341013.
10 citations·PubMed·Publisher's Site
2015
Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.
JACC. Cardiovascular interventions.8(11):1457-1467[DOI] 10.1016/j.jcin.2015.02.030.[PMID] 26404199.
68 citations·PubMed·Publisher's Site
2015
Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike.
Progress in cardiovascular diseases.58(3):267-77[DOI] 10.1016/j.pcad.2015.08.009.[PMID] 26277706.
15 citations·PubMed·Publisher's Site
2015
Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
JACC. Cardiovascular interventions.8(8):1075-1083[DOI] 10.1016/j.jcin.2015.02.022.[PMID] 26117466.
4 citations·PubMed·Publisher's Site
2015
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.
Future cardiology.11(5):547-64[DOI] 10.2217/fca.15.50.[PMID] 26406386.
16 citations·PubMed·Publisher's Site
2015
Reply: elevated serum fibrinogen: an independent link between diabetes mellitus, impaired on-clopidogrel platelet inhibition, and major adverse cardiac events after percutaneous coronary intervention.
Journal of the American College of Cardiology.65(16):1714-1715[DOI] 10.1016/j.jacc.2014.12.069.[PMID] 25908082.
PubMed·Publisher's Site
2015
Role of thromboelastography and rapid thromboelastography to assess the pharmacodynamic effects of vitamin K antagonists.
Journal of thrombosis and thrombolysis.40(1):118-25[DOI] 10.1007/s11239-014-1130-1.[PMID] 25129122.
13 citations·PubMed·Publisher's Site
2014
Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.
Journal of cardiovascular translational research.7(1):53-63[DOI] 10.1007/s12265-013-9535-3.[PMID] 24395495.
21 citations·PubMed·Publisher's Site
2014
Erratum to: Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
Journal of thrombosis and thrombolysis.37(3):358-[DOI] 10.1007/s11239-013-1003-z.[PMID] 24101257.
PubMed·Publisher's Site
2014
Impact of cigarette smoking on P2Y12 receptor binding activity before and after clopidogrel therapy in patients with coronary artery disease.
Journal of cardiovascular translational research.7(1):47-52[DOI] 10.1007/s12265-013-9530-8.[PMID] 24357254.
7 citations·PubMed·Publisher's Site
2014
Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.
Journal of the American College of Cardiology.64(10):1005-14[DOI] 10.1016/j.jacc.2014.06.1170.[PMID] 25190236.
140 citations·PubMed·Publisher's Site
2014
Perspectives on the management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery.
Current opinion in cardiology.29(6):553-63[DOI] 10.1097/HCO.0000000000000104.[PMID] 25144343.
5 citations·PubMed·Publisher's Site
2014
Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
JACC. Cardiovascular interventions.7(4):426-34[DOI] 10.1016/j.jcin.2013.11.019.[PMID] 24630878.
30 citations·PubMed·Publisher's Site
2014
Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
Journal of thrombosis and thrombolysis.37(2):131-8[DOI] 10.1007/s11239-013-0979-8.[PMID] 23943337.
11 citations·PubMed·Publisher's Site
2014
Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
Thrombosis and haemostasis.111(2):258-65[DOI] 10.1160/TH13-07-0529.[PMID] 24154863.
10 citations·PubMed·Publisher's Site
2014
Platelet function testing in contemporary clinical and interventional practice.
Current treatment options in cardiovascular medicine.16(5):300-[DOI] 10.1007/s11936-014-0300-y.[PMID] 24652579.
34 citations·PubMed·Publisher's Site
2014
Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.
Vascular health and risk management.10():177-88[DOI] 10.2147/VHRM.S36045.[PMID] 24729713.
14 citations·PubMed·Publisher's Site
2013
Cangrelor: a review on pharmacology and clinical trial development.
Expert review of cardiovascular therapy.11(10):1279-91[DOI] 10.1586/14779072.2013.837701.[PMID] 24138516.
57 citations·PubMed·Publisher's Site
2013
Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation.
Journal of thrombosis and thrombolysis.35(2):155-64[DOI] 10.1007/s11239-012-0846-z.[PMID] 23184484.
22 citations·PubMed·Publisher's Site
2013
Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation.
Thrombosis and haemostasis.110(4):777-84[DOI] 10.1160/TH13-05-0400.[PMID] 23884248.
7 citations·PubMed·Publisher's Site
2013
Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy.
JACC. Cardiovascular interventions.6(2):182-4[DOI] 10.1016/j.jcin.2012.10.007.[PMID] 23428011.
10 citations·PubMed·Publisher's Site
2013
Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus.
Journal of thrombosis and thrombolysis.36(1):14-7[DOI] 10.1007/s11239-012-0828-1.[PMID] 23143668.
14 citations·PubMed·Publisher's Site
2013
Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.81(1):42-9[DOI] 10.1002/ccd.24416.[PMID] 22431415.
16 citations·PubMed·Publisher's Site
2013
Platelet function profiles in patients with diabetes mellitus.
Journal of cardiovascular translational research.6(3):329-45[DOI] 10.1007/s12265-013-9449-0.[PMID] 23404189.
41 citations·PubMed·Publisher's Site
2013
Switching from prasugrel to clopidogrel: navigating in unknown waters.
JACC. Cardiovascular interventions.6(2):166-8[DOI] 10.1016/j.jcin.2012.12.001.[PMID] 23428008.
7 citations·PubMed·Publisher's Site
2013
Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice.
Therapeutic advances in cardiovascular disease.7(4):197-213[DOI] 10.1177/1753944713487781.[PMID] 23818658.
42 citations·PubMed·Publisher's Site
2012
[The GRAVITAS study].
Giornale italiano di cardiologia (2006).13(1):1-5[DOI] 10.1714/1015.11050.[PMID] 22322466.
PubMed·Publisher's Site
2012
Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.
Platelets.23(7):537-51[DOI] .[PMID] 22812566.
17 citations·PubMed·Publisher's Site
2012
Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.
Future cardiology.8(4):503-11[DOI] 10.2217/fca.12.35.[PMID] 22871190.
3 citations·PubMed·Publisher's Site
2012
Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus.
Thrombosis and haemostasis.108(5):930-6[DOI] 10.1160/TH12-06-0397.[PMID] 22782352.
12 citations·PubMed·Publisher's Site
2012
Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers.
Journal of thrombosis and thrombolysis.34(3):297-9[DOI] .[PMID] 22923024.
6 citations·PubMed·Publisher's Site
2011
Carotid plaque characterisation by IVUS-VH during carotid stenting: the "eyes wide shut" between plaque morphology and symptoms.
Minerva cardioangiologica.59(6):591-600[DOI] .[PMID] 22134471.
3 citations·PubMed·Publisher's Site
2011
Evaluation of re-endothelization extent at mid-term follow-up after drug eluting balloon plus bare metal stent implantation during primary coronary angioplasty: insight from OCT imaging.
Minerva cardioangiologica.59(1):109-12[DOI] .[PMID] 21285936.
1 citations·PubMed·Publisher's Site
2009
Assessing coronary heart disease in women.
Maturitas.62(3):243-7[DOI] 10.1016/j.maturitas.2008.12.013.[PMID] 19200669.
11 citations·PubMed·Publisher's Site

Office Information

Academic Office
5th Floor, Ambulatory Care Center
655 West 8th Street, C35
Jacksonville, FL 32209
(904) 244-4755
 Fabiana.rollini@jax.ufl.edu
Medical Secretary
 Monica George
(904) 244-2060
monica.george@jax.ufl.edu

Education

Medical Degree
2007 · University of Modena and Reggio Emilia, Modena, Italy
2012 · University of Modena and Reggio Emilia, Modena, Italy

News

June 26, 2023
16 UF COMJ faculty members receive promotions for 2023-24